The frequency of KRAS mutations in gastric cancer was reported as 6.67%.49 In contrast, for colorectal cancer, 1.8% of EBV-positive samples demonstrated wild-type status and 47.2% were heterozygous mutations, in contrast to the control group, which exhibited 14.7% heterozygous mutations (p < 0.01). The gene discussed is KRAS; the disease is colorectal cancer.